<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825744</url>
  </required_header>
  <id_info>
    <org_study_id>HR-TPO-SAA-III</org_study_id>
    <nct_id>NCT03825744</nct_id>
  </id_info>
  <brief_title>Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia</brief_title>
  <official_title>A Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, placebo-control, phase III study to investigate&#xD;
      hetrombopag in subjects with severe AA who are treated naive.&#xD;
&#xD;
      180 treated naive patients with SAA will be enrolled in the study. The primary objective of&#xD;
      the study will be the rate of complete hematologic response at six months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete hematologic response at six months.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Hetrombopag Olamine+Standard Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Standard Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine+Standard Therapy</intervention_name>
    <description>once daily</description>
    <arm_group_label>Hetrombopag Olamine+Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo+Standard Therapy</intervention_name>
    <description>once daily</description>
    <arm_group_label>Placebo+Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.15 Years to 75 Years (weight greater than 50 kg if Age &lt; 18 years old). 2.Severe aplastic&#xD;
        anemia characterized by Bone marrow cell proliferation less than 25 percent (If ≥25% but&#xD;
        &lt;50%, the remaining hematopoietic cells should be &lt;30%) AND At least two of the following:&#xD;
        Absolute neutrophil count &lt;0.5×109/L; Platelet count &lt;20×109/L; Absolute reticulocyte count&#xD;
        &lt;20×109/L.&#xD;
&#xD;
        3.Unsuitable or unwilling to perform hematopoietic stem cell transplantation (HSCT).&#xD;
&#xD;
        4.Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of whole blood cell reduction due to other causes or bone marrow&#xD;
             hypoproliferative diseases.&#xD;
&#xD;
          2. Subjects who have previously received immunosuppressive therapy with mycophenolate&#xD;
             mofetil, sirolimus, high dose cyclophosphamide (≥45mg/kg/d), alemtuzumab, etc；or have&#xD;
             treated with thrombopoietin receptor agonist (eg, eltrombopag, romiplostim, rhTPO,&#xD;
             etc.) prior to randomization.&#xD;
&#xD;
          3. Previous history of hematopoietic stem cell transplantation.&#xD;
&#xD;
          4. Subjects who is known or suspected of contraindications or hypersensitivity to&#xD;
             Hetrombopag's API (Active Pharmaceutical Ingredient).&#xD;
&#xD;
          5. Evidence of clonal cytogenetic abnormalities at the time of screening.&#xD;
&#xD;
          6. Bleeding and/or Infection not adequately responding to appropriate therapy.&#xD;
&#xD;
          7. Any laboratory or clinical evidence for HIV infection. Any clinical history for&#xD;
             hepatitis C infection; chronic hepatitis B infection; or any evidence for active&#xD;
             hepatitis at the time of subjects screening.&#xD;
&#xD;
          8. ALT&gt; 2.5 x upper limit of normal (ULN), AST&gt; 2.5 x upper limit of normal (ULN) DBLI&gt;&#xD;
             1.5 x upper limit of normal (ULN), Scr&gt; upper limit of normal (ULN).&#xD;
&#xD;
          9. Subjects with uncontrolled hypertension (&gt;180/100mmHg), severe arrhythmia (such as&#xD;
             complete left bundle branch block, QT interval prolongation (Bazetts formula), torsade&#xD;
             ventricular tachycardia, etc.), unstable angina, pulmonary hypertension at the time of&#xD;
             screening.&#xD;
&#xD;
         10. Subjects diagnosed with cirrhosis or portal hypertension.&#xD;
&#xD;
         11. Subjects with malignant solid tumors of any organ system within 5 years prior to&#xD;
             screening, with or without treatment, metastasis or recurrence, except for local&#xD;
             cutaneous basal cell carcinoma; subjects with hematological tumors found previously or&#xD;
             during screening.&#xD;
&#xD;
         12. Subjects with deep vein thrombosis, myocardial infarction, stroke or peripheral&#xD;
             arterial embolization within 12 months prior to randomization.&#xD;
&#xD;
         13. Female subjects who are nursing or pregnant.&#xD;
&#xD;
         14. Subjects cannot comply with effective contraception.&#xD;
&#xD;
         15. Subjects have participated in other clinical trial within the 3 months prior to study&#xD;
             entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ya-Qi Shen</last_name>
    <phone>+86-18036617093</phone>
    <email>shenyaqi@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blood Diseases Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengkui Zhang</last_name>
      <email>zhfk@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

